Literature DB >> 17347862

A comparison of two different treatments with navigated extracorporeal shock-wave therapy for calcifying tendinitis - a randomized controlled trial.

Manuel Sabeti1, Ronald Dorotka, Alexandra Goll, Martin Gruber, Klaus Dieter Schatz.   

Abstract

BACKGROUND: Extracorporeal shock-wave therapy is recommended for calcifying tendinitis, and navigated low-energy therapy has given better results than biofeedback localization. This investigation was planned to analyze whether the outcome of navigated low-energy shock-wave therapy can be improved by raising energy flux density to middle-energy levels. The clinical and radiological differences in outcome between three sessions of low-energy navigated shock-wave therapy and two sessions of middle-energy therapy were therefore compared. PATIENTS,
MATERIALS AND METHODS: A prospective, randomized, observer-blind study was carried out in 50 patients whose mean age was 51 years. The population was randomized into two groups. Pain refractory to therapy was evident for more than six months in all patients. Radiographs and clinical examinations, including the Constant and Murley score, and the visual analog scale for pain assessment were performed before therapy and then after 12 weeks. Both groups of patients received navigated and X-ray-assisted, focused shock-wave treatment at weekly intervals. Group I underwent three sessions of constant low-energy treatment (0.08 mJ/mm(2); 1000 impulses) without local anesthesia; Group II received two middle-energy treatments (0.2 mJ/mm(2); 2000 impulses) with subacromial anesthesia.
RESULTS: Forty-four patients (21 in Group I, 23 in Group II) completed the study protocol. Clinically, both groups improved significantly (P<0.0001) in the Constant and Murley score and the visual analog scale. The statistics within the groups were not significantly different. Overall, nine calcium deposits disappeared and 12 changed massively in shape and radiological density.
CONCLUSIONS: Navigated shock-wave therapy significantly improves pain and shoulder function. Patients obtained nearly equal results after three low-energy or two middle-energy sessions of shock-wave treatment. We therefore recommend two sessions of middle-energy shock-wave therapy, as performed in Group II, because of the time-saving factor.

Entities:  

Mesh:

Year:  2007        PMID: 17347862     DOI: 10.1007/s00508-006-0723-x

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  13 in total

1.  [Extracorporeal shockwave therapy in tendionosis calcarea of the rotator cuff: comparison of different treatment protocols].

Authors:  R Seil; S Rupp; D S Hammer; S Ensslin; T Gebhardt; D Kohn
Journal:  Z Orthop Ihre Grenzgeb       Date:  1999 Jul-Aug

2.  Subacromial/subdeltoid septic bursitis associated with isotretinoin therapy and corticosteroid injection.

Authors:  Jonathan A Drezner; Brian J Sennett
Journal:  J Am Board Fam Pract       Date:  2004 Jul-Aug

3.  [Prevalence of self-reported musculoskeletal pain in the Austrian population].

Authors:  Martin Friedrich; Thomas Rustler; Julia Hahne
Journal:  Wien Klin Wochenschr       Date:  2006-03       Impact factor: 1.704

4.  Extracorporeal shock wave therapy in the treatment of calcific tendinitis of the rotator cuff.

Authors:  Manuel Sabeti-Aschraf; Ronald Dorotka; Alexandra Goll; Klemens Trieb
Journal:  Am J Sports Med       Date:  2005-07-07       Impact factor: 6.202

5.  A clinical method of functional assessment of the shoulder.

Authors:  C R Constant; A H Murley
Journal:  Clin Orthop Relat Res       Date:  1987-01       Impact factor: 4.176

6.  Extracorporeal shockwave treatment is effective in calcific tendonitis of the shoulder. A randomized controlled trial.

Authors:  Johannes Pleiner; Richard Crevenna; Herbert Langenberger; Mohammad Keilani; Martin Nuhr; Franz Kainberger; Michael Wolzt; Günther Wiesinger; Michael Quittan
Journal:  Wien Klin Wochenschr       Date:  2004-08-31       Impact factor: 1.704

7.  Shock wave therapy for calcific tendinitis of the shoulder: a prospective clinical study with two-year follow-up.

Authors:  Ching-Jen Wang; Kuender D Yang; Feng-Sheng Wang; Han-Hsiang Chen; Jun-Wen Wang
Journal:  Am J Sports Med       Date:  2003 May-Jun       Impact factor: 6.202

8.  Osteonecrosis of the humeral head after extracorporeal shock-wave lithotripsy.

Authors:  H B Durst; G Blatter; M S Kuster
Journal:  J Bone Joint Surg Br       Date:  2002-07

9.  [Extracorporeal shockwave therapy (ESWT) in tendinosis calcarea of the rotator cuff. Long-term results and efficacy].

Authors:  W Daecke; D Kusnierczak; M Loew
Journal:  Orthopade       Date:  2002-07       Impact factor: 1.087

10.  Extracorporeal shock wave therapy for the treatment of chronic calcifying tendonitis of the rotator cuff: a randomized controlled trial.

Authors:  Ludger Gerdesmeyer; Stefan Wagenpfeil; Michael Haake; Markus Maier; Markus Loew; Klaus Wörtler; Renee Lampe; Romain Seil; Gerhart Handle; Susanne Gassel; Jan D Rompe
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

View more
  4 in total

1.  Extracorporeal shockwave therapy in calcifying tendinitis of the shoulder.

Authors:  Sebastian Farr; Florian Sevelda; Patrick Mader; Alexandra Graf; Gert Petje; Manuel Sabeti-Aschraf
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-03-23       Impact factor: 4.342

2.  Focused extracorporeal shock wave therapy in calcifying tendinitis of the shoulder: a meta-analysis.

Authors:  Patrick Vavken; Johannes Holinka; Jan Dirk Rompe; Ronald Dorotka
Journal:  Sports Health       Date:  2009-03       Impact factor: 3.843

3.  Shock wave therapy for rotator cuff disease with or without calcification.

Authors:  Stephen J Surace; Jessica Deitch; Renea V Johnston; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2020-03-04

Review 4.  Efficacy and safety of extracorporeal shock wave therapy for orthopedic conditions: a systematic review on studies listed in the PEDro database.

Authors:  Christoph Schmitz; Nikolaus B M Császár; Stefan Milz; Matthias Schieker; Nicola Maffulli; Jan-Dirk Rompe; John P Furia
Journal:  Br Med Bull       Date:  2015-11-18       Impact factor: 4.291

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.